FDA approves Abilify

Share this content:
Bristol-Myers Squibb and Otsuka Pharmaceutical Company won FDA approval for Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Share this content:
Scroll down to see the next article